Trial · NCT00338286
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival | Standard of Care (SOC) | 7.4 | 95% Confidence Interval 7.1 to 7.6 | Months | |
| Progression Free Survival | Epoetin Alfa | 7.4 | 95% Confidence Interval 6.9 to 7.6 | Months | |
| Overall Survival | Standard of Care (SOC) | 18.0 | 95% Confidence Interval 16.6 to 19.6 | Months | |
| Overall Survival | Epoetin Alfa | 17.8 | 95% Confidence Interval 16.6 to 19.1 | Months | |
| Time to Tumor Progression | Standard of Care (SOC) | 7.5 | 95% Confidence Interval 7.4 to 8.0 | Months | |
| Time to Tumor Progression | Epoetin Alfa | 7.5 | 95% Confidence Interval 7.4 to 7.9 | Months | |
| Overall Response Rate (ORR) | Standard of Care (SOC) | Complete response (CR) | 3 | Percentage of participants | |
| Overall Response Rate (ORR) | Epoetin Alfa | Complete response (CR) | 3 | Percentage of participants | |
| Overall Response Rate (ORR) | Standard of Care (SOC) | Partial response (PR) | 48 | Percentage of participants | |
| Overall Response Rate (ORR) | Epoetin Alfa | Partial response (PR) | 47 | Percentage of participants | |
| Overall Response Rate (ORR) | Standard of Care (SOC) | Stable disease (SD) | 30 | Percentage of participants | |
| Overall Response Rate (ORR) | Epoetin Alfa | Stable disease (SD) | 32 | Percentage of participants | |
| Overall Response Rate (ORR) | Standard of Care (SOC) | Progressive disease (PD) | 13 | Percentage of participants | |
| Overall Response Rate (ORR) | Epoetin Alfa | Progressive disease (PD) | 12 | Percentage of participants | |
| Overall Response Rate (ORR) | Standard of Care (SOC) | Not evaluable (NE) | 1 | Percentage of participants | |
| Overall Response Rate (ORR) | Epoetin Alfa | Not evaluable (NE) | 2 | Percentage of participants | |
| Overall Response Rate (ORR) | Standard of Care (SOC) | Not available (NA) | 5 | Percentage of participants | |
| Overall Response Rate (ORR) | Epoetin Alfa | Not available (NA) | 5 | Percentage of participants | |
| Percentage of Participants With Suspected Thrombotic Vascular Events (TVEs) | Standard of Care (SOC) | 3.72 | Percentage of participants | ||
| Percentage of Participants With Suspected Thrombotic Vascular Events (TVEs) | Epoetin Alfa | 4.86 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00338286/results